secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2023-09-20T23:59:59+00:00
Accession:  0001193125-23-237996
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharma receives FDA Complete Response Letter for neffy; plans appeal, resubmission H1 2024
--------------------------------------------------------------------------------

- FDA CRL requests a repeat-dose PK/PD study in allergen-induced allergic rhinitis conditions for approval.
- Company will file a Formal Dispute Resolution Request to appeal the CRL; advisory committee voted 16-6/17-5 in favor May 2023.
- CRL also asks for nitrosamine impurity testing; company says not rate-limiting for resubmission.
- Resubmission expected first half 2024 with FDA action target second half 2024.
- Prior FDA alignment on the repeat-dose study as a post-marketing commitment; CRL now requires it for approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312523237996/0001193125-23-237996-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312523237996/d556858d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-237996

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer